Diabetes Drug Proving to Have Beneficial Effects

Monash University's Eastern Clinical Research Unit is leading research on investigating the beneficial side of a new glocuse-regulating medication for diabetes sufferers.

A pre-clinical study, published in the journal Diabetes and Vascular Disease Research, demonstrated potentially beneficial effects of the drug in improving or stabilising diabetic vascular disease.

Dr Anthony Dear and Professor Richard Simpson from Monash University’s Eastern Clinical Research Unit are leading the research team. Dr Dear said the drug's potential was important, as Type 2 diabetics often had poor cardiovascular health.

"As the global epidemic of diabetes escalates, this drug has the potential to offer tremendous help to millions of diabetics worldwide," Dr Dear said.

"Pre-clinical studies suggest the drug may improve vascular health in Type 2 diabetics. We think it may have the potential to reduce heart attacks and strokes in those diabetics whose cardiovascular systems are damaged due to the disease. "Lots of drugs lower blood sugar but they don't necessarily protect blood vessels."

Dr Dear said the drug was derived from the natural gut hormone, Glucagon-Like Peptide-1 (GLP-1).

“It effectively lowers blood glucose by stimulating insulin release in the body. It is a derivative of a naturally-occurring substance which appears to have receptors for it on the surface of blood vessel cells in addition to the pancreas, suggesting it may also have an effect on blood vessel disease,” Dr Dear said. "We think it may also 'smooth' the surface of vessel walls and make them less sticky and prone to develop ‘blockages’ - a condition frequently seen in Type 2 diabetics. This would mean that blockages, often contributing to the cause of heart attacks and strokes, would be less likely to form."

Dr Dear said the drug might have the extra potential to improve some of the challenges experienced by diabetics, including weight loss.

“One of the effects of the drug, and natural hormone from which the drug is derived, is to cause weight loss,” Dr Dear said. “Its benefits outside of lowering blood-sugar levels are conducive to problems that diabetics may have, such as being overweight or accelerated blood vessel disease.”

The research is being conducted by the Eastern Clinical Research Unit, Translational Research Division at Monash in collaboration with the University’s Department of Pharmacology.

The World Health Organisation reports that more that more than 347 million people worldwide live with diabetes and around 90 per cent of these cases are Type 2